Aurobindo Pharma Ltd Board of Directors
Board of Directors at Aurobindo Pharma Ltd
Independent Director
Independent Director
Vice Chairman & M.D.
Whole-time Director
Chairman & Independent Directo
Key Highlights
- M R Kumar joins the board as Chairman & Independent Directo, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- Kambam Nityananda Reddy joins the board as Vice Chairman & M.D., in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- M Madan Mohan Reddy joins the board as E D & Wholetime Director, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- P V Ramprasad Reddy continues to serve as the Non Executive Director in 2026, maintaining the same position as in the previous year.
- Penaka Sarath Chandra Reddy joins the board as Non-Exec & Non-Independent Dir, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
Aurobindo Pharma Ltd
NSE: AUROPHARMA
Share Price
Last Ten Days Market Price
| Date | |
|---|---|
| 03 Sep 2026 | 1627 |
| 02 Sep 2026 | 1656.3 |
| 01 Sep 2026 | 1683 |
| 31 Aug 2026 | 1690 |
| 28 Aug 2026 | 1650 |
| 27 Aug 2026 | 1631 |
| 26 Aug 2026 | 1622 |
| 25 Aug 2026 | 1603.25 |
| 24 Aug 2026 | 1609.6 |
| 21 Aug 2026 | 1619.95 |
Company Fundamentals for Aurobindo Pharma Ltd
Market Cap
93,613 Cr
EPS
65.7
P/E Ratio (TTM)
24.8
P/B Ratio (TTM)
2.5
Day’s High
1660.6
Day’s Low
1623.05
DTE
0.2
ROE
9.2
52 Week High
1706.7
52 Week Low
1020.0
ROCE
11.8
Market Price of Aurobindo Pharma Ltd
1M
1Y
3Y
5Y
Aurobindo Pharma Ltd News Hub
Aurobindo Pharma tumbles after US FDA issues warning letter to Telangana unit
In May 2024, the United States Food and Drug Administration (US FDA) had conducted an inspection at
Read more
16 Aug 24
Eugia Pharma Specialities receives USFDA warning for Unit III
Aurobindo Pharma announced that the USFDA has issued a warning letter for Unit-III of Eugia Pharma S
Read more
16 Aug 24
Aurobindo Pharma consolidated net profit rises 61.05% in the June 2024 quarter
Net profit of Aurobindo Pharma rose 61.05% to Rs 919.22 crore in the quarter ended June 2024 as agai
Read more
12 Aug 24
Auro Pharma Q3 PAT slides 10% YoY to Rs 846 crore
However, revenue from operations increased 8.53% year on year (YoY) to Rs 7,978.52 crore in the quar
Read more
07 Feb 25
Document
Concalls
